Search

Your search keyword '"Rolland, Morgane"' showing total 469 results

Search Constraints

Start Over You searched for: Author "Rolland, Morgane" Remove constraint Author: "Rolland, Morgane"
469 results on '"Rolland, Morgane"'

Search Results

1. Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.

2. Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques

3. Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption

4. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

5. Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity

6. Defining the risk of SARS-CoV-2 variants on immune protection

7. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain

8. US National Institutes of Health Prioritization of SARS-CoV-2 Variants

9. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine

10. An active HIV reservoir during ART is associated with maintenance of HIV-specific CD8+ T cell magnitude and short-lived differentiation status

11. Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes

12. Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand

13. Acute HIV-1 infection viremia associate with rebound upon treatment interruption

14. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

15. Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding

16. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

20. Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey

21. Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features

22. Evolution of HIV-1 envelope towards reduced neutralization sensitivity, as demonstrated by contemporary HIV-1 subtype B from the United States

23. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound

24. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor

25. Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

26. Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.

28. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

30. Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis

32. Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection

33. Definition of the viral targets of protective HIV-1-specific T cell responses

34. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity

36. Coping with Viral Diversity in HIV Vaccine Design

37. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection

38. Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

44. Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells

46. Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand

47. Defining the risk of SARS-CoV-2 variants on immune protection

48. HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders

49. Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection

Catalog

Books, media, physical & digital resources